 Robert MacLaren
Concepts (487)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 46 | 2025 | 758 | 7.310 |
Why?
| | Intensive Care Units | 40 | 2024 | 738 | 5.150 |
Why?
| | Critical Care | 25 | 2025 | 553 | 4.920 |
Why?
| | Peptic Ulcer | 9 | 2023 | 18 | 4.030 |
Why?
| | Gastrointestinal Hemorrhage | 8 | 2024 | 121 | 3.590 |
Why?
| | Hypnotics and Sedatives | 12 | 2024 | 175 | 3.460 |
Why?
| | Pharmacy Service, Hospital | 10 | 2024 | 90 | 3.220 |
Why?
| | Histamine H2 Antagonists | 9 | 2024 | 29 | 3.060 |
Why?
| | Enteral Nutrition | 13 | 2023 | 188 | 2.980 |
Why?
| | Proton Pump Inhibitors | 9 | 2024 | 100 | 2.950 |
Why?
| | Pharmacists | 10 | 2024 | 247 | 2.790 |
Why?
| | Dexmedetomidine | 9 | 2019 | 43 | 2.740 |
Why?
| | Gastric Emptying | 8 | 2017 | 40 | 1.970 |
Why?
| | Midazolam | 4 | 2024 | 53 | 1.640 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2022 | 176 | 1.580 |
Why?
| | Shock, Septic | 4 | 2022 | 209 | 1.510 |
Why?
| | Anticoagulants | 12 | 2023 | 637 | 1.440 |
Why?
| | Epoprostenol | 2 | 2023 | 136 | 1.410 |
Why?
| | Heparin | 7 | 2023 | 253 | 1.350 |
Why?
| | Professional Role | 5 | 2024 | 158 | 1.250 |
Why?
| | Metoclopramide | 7 | 2010 | 19 | 1.240 |
Why?
| | Vasopressins | 4 | 2022 | 64 | 1.170 |
Why?
| | Sepsis | 7 | 2023 | 574 | 1.120 |
Why?
| | Stress, Physiological | 5 | 2021 | 413 | 1.120 |
Why?
| | Adult | 54 | 2024 | 35577 | 1.100 |
Why?
| | Lorazepam | 4 | 2014 | 26 | 1.090 |
Why?
| | Retrospective Studies | 39 | 2024 | 14518 | 1.080 |
Why?
| | Hemorrhage | 9 | 2021 | 678 | 1.070 |
Why?
| | Pneumonia | 5 | 2022 | 616 | 1.060 |
Why?
| | Visual Acuity | 4 | 2024 | 322 | 1.010 |
Why?
| | Humans | 115 | 2025 | 129652 | 1.010 |
Why?
| | Factor VIIa | 5 | 2016 | 39 | 0.980 |
Why?
| | Thrombelastography | 2 | 2023 | 150 | 0.950 |
Why?
| | Thromboembolism | 2 | 2020 | 112 | 0.950 |
Why?
| | Vasoconstrictor Agents | 5 | 2023 | 127 | 0.940 |
Why?
| | Neurosurgical Procedures | 2 | 2024 | 173 | 0.940 |
Why?
| | Gastrointestinal Agents | 5 | 2010 | 61 | 0.930 |
Why?
| | Recombinant Proteins | 13 | 2023 | 1304 | 0.920 |
Why?
| | Proton Pumps | 2 | 2014 | 8 | 0.910 |
Why?
| | Propofol | 5 | 2019 | 60 | 0.910 |
Why?
| | Ulcer | 1 | 2023 | 29 | 0.840 |
Why?
| | Alcoholism | 2 | 2022 | 766 | 0.790 |
Why?
| | Blood Coagulation Factors | 3 | 2020 | 53 | 0.760 |
Why?
| | Burns | 3 | 2018 | 286 | 0.760 |
Why?
| | Hypothermia, Induced | 2 | 2013 | 76 | 0.740 |
Why?
| | Hypotension | 2 | 2022 | 116 | 0.740 |
Why?
| | Oseltamivir | 1 | 2021 | 11 | 0.720 |
Why?
| | Anti-Ulcer Agents | 3 | 2017 | 15 | 0.710 |
Why?
| | Analgesia | 2 | 2018 | 100 | 0.710 |
Why?
| | Stress, Psychological | 4 | 2024 | 1066 | 0.700 |
Why?
| | Rhodopsin | 1 | 2020 | 10 | 0.690 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2020 | 14 | 0.690 |
Why?
| | Retinal Degeneration | 1 | 2020 | 37 | 0.670 |
Why?
| | Dependovirus | 1 | 2020 | 62 | 0.660 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 284 | 0.660 |
Why?
| | Conscious Sedation | 2 | 2013 | 85 | 0.660 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 221 | 0.660 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2023 | 282 | 0.640 |
Why?
| | Vision Tests | 1 | 2019 | 16 | 0.640 |
Why?
| | Vision, Low | 1 | 2019 | 16 | 0.640 |
Why?
| | Middle Aged | 42 | 2024 | 31155 | 0.640 |
Why?
| | Esomeprazole | 1 | 2018 | 6 | 0.620 |
Why?
| | Genetic Vectors | 1 | 2020 | 312 | 0.620 |
Why?
| | Fibrinolytic Agents | 3 | 2016 | 263 | 0.620 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 211 | 0.610 |
Why?
| | Fluid Therapy | 3 | 2023 | 134 | 0.600 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 790 | 0.600 |
Why?
| | Genetic Therapy | 1 | 2020 | 292 | 0.590 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 393 | 0.580 |
Why?
| | APACHE | 3 | 2010 | 65 | 0.580 |
Why?
| | Phenytoin | 1 | 2017 | 20 | 0.580 |
Why?
| | Erythromycin | 4 | 2010 | 25 | 0.560 |
Why?
| | Ketamine | 1 | 2018 | 85 | 0.560 |
Why?
| | Blood Coagulation Disorders | 2 | 2016 | 167 | 0.550 |
Why?
| | Male | 52 | 2024 | 63682 | 0.550 |
Why?
| | Albumins | 1 | 2017 | 103 | 0.550 |
Why?
| | Ethanol | 3 | 2022 | 589 | 0.540 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2015 | 24 | 0.540 |
Why?
| | Plasma | 2 | 2016 | 206 | 0.530 |
Why?
| | Anticonvulsants | 2 | 2017 | 209 | 0.500 |
Why?
| | Aged | 28 | 2024 | 22104 | 0.500 |
Why?
| | Female | 49 | 2025 | 68777 | 0.490 |
Why?
| | Blood Coagulation | 2 | 2007 | 238 | 0.490 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2015 | 16 | 0.480 |
Why?
| | Partial Thromboplastin Time | 4 | 2023 | 52 | 0.480 |
Why?
| | Acetaminophen | 5 | 2010 | 246 | 0.470 |
Why?
| | Nerve Growth Factor | 1 | 2015 | 27 | 0.470 |
Why?
| | Hydrocortisone | 1 | 2017 | 307 | 0.470 |
Why?
| | Community-Acquired Infections | 2 | 2014 | 161 | 0.470 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 28 | 0.470 |
Why?
| | Influenza, Human | 1 | 2021 | 601 | 0.460 |
Why?
| | Nitric Oxide | 1 | 2020 | 902 | 0.460 |
Why?
| | Stomach Diseases | 2 | 2011 | 20 | 0.450 |
Why?
| | Epinephrine | 1 | 2015 | 141 | 0.450 |
Why?
| | Drug Monitoring | 3 | 2017 | 216 | 0.450 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 114 | 0.440 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 718 | 0.440 |
Why?
| | Antifibrinolytic Agents | 2 | 2007 | 47 | 0.440 |
Why?
| | Erythropoietin | 2 | 2005 | 86 | 0.430 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1368 | 0.430 |
Why?
| | Polyvinyl Chloride | 1 | 2013 | 8 | 0.430 |
Why?
| | Hippocampus | 1 | 2018 | 874 | 0.420 |
Why?
| | Prospective Studies | 14 | 2024 | 7133 | 0.420 |
Why?
| | Hemodynamics | 2 | 2019 | 1090 | 0.420 |
Why?
| | Voriconazole | 3 | 2019 | 20 | 0.410 |
Why?
| | Sodium Chloride | 1 | 2013 | 138 | 0.400 |
Why?
| | Cross Infection | 4 | 2008 | 218 | 0.390 |
Why?
| | Mental Recall | 1 | 2013 | 192 | 0.390 |
Why?
| | Pain | 1 | 2018 | 789 | 0.390 |
Why?
| | Drug Resistance | 2 | 2011 | 166 | 0.380 |
Why?
| | Double-Blind Method | 7 | 2020 | 1876 | 0.370 |
Why?
| | Gastrointestinal Hormones | 1 | 2011 | 8 | 0.370 |
Why?
| | Ghrelin | 1 | 2011 | 33 | 0.370 |
Why?
| | Hirudins | 4 | 2023 | 52 | 0.370 |
Why?
| | Pseudomonas Infections | 4 | 2010 | 221 | 0.370 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2023 | 29 | 0.360 |
Why?
| | Cohort Studies | 8 | 2023 | 5420 | 0.360 |
Why?
| | Cisapride | 2 | 2001 | 5 | 0.360 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 641 | 0.360 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2011 | 24 | 0.360 |
Why?
| | Neuromuscular Blockade | 1 | 2011 | 22 | 0.360 |
Why?
| | Coagulants | 2 | 2008 | 15 | 0.350 |
Why?
| | Infusions, Intravenous | 6 | 2016 | 400 | 0.350 |
Why?
| | Factor VII | 2 | 2007 | 22 | 0.340 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2010 | 119 | 0.340 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 176 | 0.340 |
Why?
| | Factor Xa | 2 | 2021 | 32 | 0.330 |
Why?
| | Tachyphylaxis | 1 | 2009 | 3 | 0.330 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 11 | 0.330 |
Why?
| | Propylene Glycol | 1 | 2009 | 10 | 0.330 |
Why?
| | Surveys and Questionnaires | 8 | 2020 | 5406 | 0.330 |
Why?
| | Antiemetics | 3 | 2010 | 41 | 0.330 |
Why?
| | Heart Arrest | 1 | 2013 | 321 | 0.330 |
Why?
| | Drug Therapy, Combination | 6 | 2017 | 1040 | 0.330 |
Why?
| | Treatment Outcome | 14 | 2024 | 10230 | 0.330 |
Why?
| | Mutation | 2 | 2020 | 3717 | 0.330 |
Why?
| | Protein C | 1 | 2010 | 47 | 0.320 |
Why?
| | Factor Xa Inhibitors | 2 | 2023 | 170 | 0.320 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 18 | 0.320 |
Why?
| | Respiration, Artificial | 6 | 2019 | 613 | 0.320 |
Why?
| | Pseudomonas aeruginosa | 4 | 2010 | 347 | 0.310 |
Why?
| | International Normalized Ratio | 2 | 2016 | 46 | 0.310 |
Why?
| | Attitude of Health Personnel | 2 | 2014 | 1098 | 0.310 |
Why?
| | Bradycardia | 3 | 2021 | 53 | 0.310 |
Why?
| | Hemofiltration | 3 | 2017 | 30 | 0.300 |
Why?
| | Lung Diseases | 2 | 2007 | 742 | 0.300 |
Why?
| | Central Serous Chorioretinopathy | 2 | 2020 | 3 | 0.300 |
Why?
| | Immune System | 1 | 2009 | 175 | 0.290 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2005 | 71 | 0.290 |
Why?
| | Antifungal Agents | 3 | 2019 | 129 | 0.290 |
Why?
| | Photochemotherapy | 2 | 2020 | 32 | 0.290 |
Why?
| | Nursing Audit | 1 | 2007 | 6 | 0.290 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2024 | 582 | 0.280 |
Why?
| | Anesthesia | 1 | 2009 | 134 | 0.280 |
Why?
| | Forms and Records Control | 1 | 2007 | 22 | 0.280 |
Why?
| | Peptide Fragments | 3 | 2023 | 692 | 0.280 |
Why?
| | Hemostatics | 1 | 2007 | 49 | 0.270 |
Why?
| | Physicians | 2 | 2013 | 865 | 0.270 |
Why?
| | Triazoles | 2 | 2019 | 152 | 0.270 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 524 | 0.270 |
Why?
| | Bacterial Infections | 1 | 2008 | 237 | 0.260 |
Why?
| | Risk Management | 1 | 2007 | 85 | 0.260 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2014 | 544 | 0.260 |
Why?
| | Anesthetics | 1 | 2007 | 66 | 0.260 |
Why?
| | Dopamine Antagonists | 2 | 2008 | 23 | 0.260 |
Why?
| | Anti-Bacterial Agents | 5 | 2022 | 1717 | 0.260 |
Why?
| | Glutamine | 1 | 2007 | 99 | 0.260 |
Why?
| | Clinical Pharmacy Information Systems | 1 | 2006 | 6 | 0.260 |
Why?
| | Models, Economic | 1 | 2006 | 53 | 0.260 |
Why?
| | Respiration | 1 | 2007 | 191 | 0.260 |
Why?
| | Factor VII Deficiency | 1 | 2005 | 4 | 0.250 |
Why?
| | Fentanyl | 3 | 2018 | 79 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1266 | 0.250 |
Why?
| | Analgesics, Opioid | 3 | 2018 | 913 | 0.240 |
Why?
| | Intubation, Gastrointestinal | 2 | 2008 | 77 | 0.240 |
Why?
| | Common Data Elements | 1 | 2025 | 12 | 0.240 |
Why?
| | Aged, 80 and over | 9 | 2024 | 7086 | 0.240 |
Why?
| | Risk Factors | 9 | 2023 | 9765 | 0.240 |
Why?
| | Intravitreal Injections | 1 | 2024 | 56 | 0.230 |
Why?
| | Macular Edema | 1 | 2024 | 42 | 0.220 |
Why?
| | Antidotes | 2 | 2016 | 136 | 0.220 |
Why?
| | Time Factors | 10 | 2018 | 6556 | 0.220 |
Why?
| | Drug Interactions | 2 | 2023 | 394 | 0.220 |
Why?
| | Delphi Technique | 1 | 2025 | 225 | 0.210 |
Why?
| | Regression Analysis | 3 | 2017 | 993 | 0.210 |
Why?
| | Anemia | 1 | 2005 | 160 | 0.210 |
Why?
| | Clostridium Infections | 2 | 2014 | 64 | 0.210 |
Why?
| | Patients' Rooms | 1 | 2022 | 13 | 0.210 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 40 | 0.210 |
Why?
| | Erythrocyte Transfusion | 1 | 2005 | 181 | 0.210 |
Why?
| | Cross-Over Studies | 3 | 2020 | 521 | 0.210 |
Why?
| | Angiogenesis Inhibitors | 1 | 2024 | 220 | 0.200 |
Why?
| | Biological Availability | 1 | 2023 | 147 | 0.200 |
Why?
| | Warfarin | 2 | 2007 | 147 | 0.200 |
Why?
| | Microbial Sensitivity Tests | 3 | 2018 | 352 | 0.200 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 1952 | 0.200 |
Why?
| | United States | 8 | 2024 | 13903 | 0.200 |
Why?
| | Renal Replacement Therapy | 2 | 2015 | 87 | 0.190 |
Why?
| | Antacids | 1 | 2001 | 16 | 0.190 |
Why?
| | Colorado | 7 | 2017 | 4421 | 0.190 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1022 | 0.190 |
Why?
| | Health Care Costs | 1 | 2005 | 367 | 0.190 |
Why?
| | Minnesota | 1 | 2022 | 149 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 530 | 0.190 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 248 | 0.180 |
Why?
| | Vitamin K 1 | 1 | 2001 | 3 | 0.180 |
Why?
| | Norepinephrine | 1 | 2022 | 210 | 0.180 |
Why?
| | Prothrombin | 1 | 2021 | 20 | 0.180 |
Why?
| | Incidence | 3 | 2022 | 2644 | 0.180 |
Why?
| | Stomach Ulcer | 2 | 2019 | 11 | 0.180 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2001 | 34 | 0.180 |
Why?
| | Catheters | 1 | 2021 | 68 | 0.180 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 171 | 0.180 |
Why?
| | Statistics, Nonparametric | 3 | 2016 | 422 | 0.180 |
Why?
| | Decision Support Techniques | 3 | 2014 | 396 | 0.170 |
Why?
| | Resuscitation | 1 | 2023 | 237 | 0.170 |
Why?
| | Light Coagulation | 1 | 2020 | 9 | 0.170 |
Why?
| | Length of Stay | 4 | 2014 | 1127 | 0.170 |
Why?
| | Inflammation | 1 | 2011 | 2736 | 0.170 |
Why?
| | Gene Knock-In Techniques | 1 | 2020 | 53 | 0.170 |
Why?
| | Thrombolytic Therapy | 1 | 2021 | 137 | 0.170 |
Why?
| | Area Under Curve | 3 | 2014 | 304 | 0.170 |
Why?
| | Retinitis Pigmentosa | 1 | 2019 | 20 | 0.170 |
Why?
| | Photosensitizing Agents | 2 | 2020 | 31 | 0.160 |
Why?
| | Ischemia | 1 | 2023 | 406 | 0.160 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4063 | 0.160 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 10 | 0.160 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 827 | 0.160 |
Why?
| | Refraction, Ocular | 1 | 2019 | 36 | 0.160 |
Why?
| | Biometry | 1 | 2019 | 69 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 1 | 2002 | 522 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2012 | 0.150 |
Why?
| | Electric Stimulation Therapy | 1 | 2019 | 77 | 0.150 |
Why?
| | Restraint, Physical | 1 | 2018 | 68 | 0.150 |
Why?
| | United Kingdom | 1 | 2019 | 258 | 0.150 |
Why?
| | Patient Care | 1 | 2019 | 109 | 0.150 |
Why?
| | Hospital Costs | 2 | 2009 | 114 | 0.150 |
Why?
| | Administration, Inhalation | 1 | 2020 | 666 | 0.150 |
Why?
| | Nitriles | 1 | 2019 | 172 | 0.150 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5066 | 0.150 |
Why?
| | Vasoconstriction | 2 | 2023 | 199 | 0.150 |
Why?
| | Wounds and Injuries | 1 | 2025 | 711 | 0.150 |
Why?
| | Oxygen | 1 | 2023 | 915 | 0.150 |
Why?
| | Patient Satisfaction | 1 | 2022 | 634 | 0.140 |
Why?
| | Random Allocation | 1 | 2018 | 346 | 0.140 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 14 | 0.140 |
Why?
| | Critical Care Nursing | 1 | 2018 | 36 | 0.140 |
Why?
| | RNA, Bacterial | 1 | 2018 | 183 | 0.140 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1997 | 28 | 0.140 |
Why?
| | Anesthetics, Intravenous | 1 | 1997 | 44 | 0.140 |
Why?
| | Vancomycin | 1 | 2018 | 78 | 0.140 |
Why?
| | Pharmacoepidemiology | 2 | 2014 | 20 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 137 | 0.140 |
Why?
| | Sucralfate | 1 | 2017 | 3 | 0.140 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 569 | 0.140 |
Why?
| | Piracetam | 1 | 2017 | 13 | 0.140 |
Why?
| | Immunity, Humoral | 1 | 2018 | 118 | 0.140 |
Why?
| | Drug Compounding | 2 | 2017 | 97 | 0.140 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 140 | 0.130 |
Why?
| | Administration, Oral | 5 | 2017 | 786 | 0.130 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 80 | 0.130 |
Why?
| | Analgesics | 1 | 2018 | 189 | 0.130 |
Why?
| | Nitroprusside | 1 | 2016 | 67 | 0.130 |
Why?
| | Thiocyanates | 1 | 2016 | 31 | 0.130 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.130 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1004 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 525 | 0.130 |
Why?
| | Pyridines | 1 | 2019 | 478 | 0.120 |
Why?
| | Academic Medical Centers | 3 | 2019 | 481 | 0.120 |
Why?
| | Thrombosis | 1 | 2019 | 343 | 0.120 |
Why?
| | Pain Management | 1 | 2018 | 327 | 0.120 |
Why?
| | Therapeutics | 1 | 2015 | 14 | 0.120 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 712 | 0.120 |
Why?
| | Methanol | 1 | 2015 | 35 | 0.120 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 27 | 0.120 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 313 | 0.120 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2119 | 0.120 |
Why?
| | Treatment Failure | 2 | 2020 | 340 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1502 | 0.110 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2014 | 12 | 0.110 |
Why?
| | Placebo Effect | 1 | 2015 | 55 | 0.110 |
Why?
| | Cardiopulmonary Bypass | 1 | 2016 | 202 | 0.110 |
Why?
| | Vasodilator Agents | 1 | 2016 | 326 | 0.110 |
Why?
| | Practice Guidelines as Topic | 4 | 2015 | 1501 | 0.110 |
Why?
| | Tomography, Optical Coherence | 3 | 2024 | 187 | 0.110 |
Why?
| | Acute Disease | 3 | 2008 | 980 | 0.110 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 6 | 0.110 |
Why?
| | Shivering | 1 | 2013 | 5 | 0.110 |
Why?
| | Osmotic Pressure | 1 | 2014 | 35 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2018 | 847 | 0.110 |
Why?
| | Laser Therapy | 1 | 2015 | 131 | 0.110 |
Why?
| | Benzodiazepines | 1 | 2014 | 136 | 0.110 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2014 | 49 | 0.110 |
Why?
| | Liver Diseases | 1 | 2016 | 290 | 0.110 |
Why?
| | Gene Expression | 1 | 2018 | 1472 | 0.110 |
Why?
| | Medicare | 2 | 2009 | 720 | 0.110 |
Why?
| | Neurologic Examination | 1 | 2013 | 115 | 0.110 |
Why?
| | Genetic Markers | 1 | 2014 | 338 | 0.110 |
Why?
| | Hemostasis | 2 | 2019 | 79 | 0.100 |
Why?
| | Drug Storage | 1 | 2013 | 57 | 0.100 |
Why?
| | Thrombocytopenia | 3 | 2018 | 186 | 0.100 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2013 | 131 | 0.100 |
Why?
| | Microphthalmos | 1 | 2013 | 1 | 0.100 |
Why?
| | Drug Packaging | 1 | 2013 | 41 | 0.100 |
Why?
| | Drug Stability | 1 | 2013 | 159 | 0.100 |
Why?
| | Injections | 1 | 2013 | 174 | 0.100 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 179 | 0.100 |
Why?
| | Propensity Score | 1 | 2014 | 265 | 0.100 |
Why?
| | Lens Implantation, Intraocular | 1 | 2013 | 59 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2014 | 559 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 253 | 0.100 |
Why?
| | Motilin | 1 | 2011 | 2 | 0.090 |
Why?
| | Cholecystokinin | 1 | 2011 | 14 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 594 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 31 | 0.090 |
Why?
| | Phacoemulsification | 1 | 2013 | 115 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2018 | 2708 | 0.090 |
Why?
| | Animals | 5 | 2020 | 35361 | 0.090 |
Why?
| | Adolescent | 8 | 2019 | 20394 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2015 | 423 | 0.090 |
Why?
| | Intraoperative Complications | 2 | 2013 | 131 | 0.090 |
Why?
| | Societies, Pharmaceutical | 2 | 2020 | 21 | 0.090 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.090 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 769 | 0.090 |
Why?
| | Lactoferrin | 1 | 2010 | 28 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5440 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2742 | 0.080 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.080 |
Why?
| | Hospitals, University | 2 | 2008 | 179 | 0.080 |
Why?
| | Databases, Factual | 2 | 2018 | 1269 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 547 | 0.080 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 122 | 0.080 |
Why?
| | Imipenem | 2 | 2010 | 18 | 0.080 |
Why?
| | Observer Variation | 1 | 2010 | 315 | 0.080 |
Why?
| | Hypoglycemia | 1 | 2013 | 427 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2024 | 4897 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2010 | 162 | 0.080 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 132 | 0.080 |
Why?
| | Pilot Projects | 1 | 2013 | 1587 | 0.070 |
Why?
| | Patient Care Team | 1 | 2013 | 605 | 0.070 |
Why?
| | Risk Assessment | 2 | 2014 | 3240 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 335 | 0.070 |
Why?
| | Quality Improvement | 3 | 2020 | 1103 | 0.070 |
Why?
| | Vitamin K | 1 | 2007 | 40 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1706 | 0.070 |
Why?
| | Blood Pressure | 2 | 2004 | 1736 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 59 | 0.070 |
Why?
| | Magnesium | 1 | 2007 | 153 | 0.070 |
Why?
| | Phosphorus | 1 | 2007 | 93 | 0.070 |
Why?
| | Potassium | 1 | 2007 | 143 | 0.070 |
Why?
| | Canada | 2 | 2014 | 350 | 0.070 |
Why?
| | Cost Control | 1 | 2006 | 39 | 0.070 |
Why?
| | Cellulitis | 1 | 2007 | 48 | 0.070 |
Why?
| | Cerebral Hemorrhage | 1 | 2007 | 107 | 0.070 |
Why?
| | Burn Units | 1 | 2007 | 42 | 0.070 |
Why?
| | Biomarkers | 2 | 2015 | 3973 | 0.070 |
Why?
| | Anxiety | 1 | 2013 | 966 | 0.070 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 485 | 0.070 |
Why?
| | Societies, Medical | 2 | 2020 | 751 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1198 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3083 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2007 | 137 | 0.060 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 9 | 0.060 |
Why?
| | Pipecolic Acids | 1 | 2005 | 25 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 384 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2282 | 0.060 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 42 | 0.060 |
Why?
| | Octreotide | 1 | 2005 | 27 | 0.060 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 82 | 0.060 |
Why?
| | Ranibizumab | 1 | 2024 | 20 | 0.060 |
Why?
| | Mice | 2 | 2020 | 16937 | 0.060 |
Why?
| | Costs and Cost Analysis | 1 | 2005 | 201 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2014 | 3381 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 1 | 2005 | 106 | 0.060 |
Why?
| | Depression | 1 | 2013 | 1307 | 0.060 |
Why?
| | Ceftazidime | 1 | 2004 | 6 | 0.060 |
Why?
| | beta-Lactam Resistance | 1 | 2004 | 8 | 0.060 |
Why?
| | Drug Substitution | 1 | 2024 | 51 | 0.060 |
Why?
| | Intraocular Pressure | 2 | 2019 | 297 | 0.060 |
Why?
| | Tobramycin | 1 | 2004 | 51 | 0.060 |
Why?
| | Ciprofloxacin | 1 | 2004 | 30 | 0.060 |
Why?
| | Sentinel Surveillance | 1 | 2004 | 41 | 0.060 |
Why?
| | Urine | 1 | 2004 | 60 | 0.060 |
Why?
| | Wet Macular Degeneration | 1 | 2024 | 46 | 0.060 |
Why?
| | Neoplasms | 1 | 2018 | 2470 | 0.060 |
Why?
| | Bevacizumab | 1 | 2024 | 129 | 0.050 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 113 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 1968 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2004 | 129 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1722 | 0.050 |
Why?
| | Adrenal Cortex | 1 | 2002 | 27 | 0.050 |
Why?
| | Skin Diseases | 1 | 2004 | 143 | 0.050 |
Why?
| | Hospital Mortality | 1 | 2007 | 850 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 3144 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2009 | 831 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 616 | 0.050 |
Why?
| | Pneumonia, Bacterial | 1 | 2003 | 115 | 0.050 |
Why?
| | Chronic Disease | 2 | 2020 | 1720 | 0.050 |
Why?
| | Young Adult | 4 | 2019 | 12427 | 0.050 |
Why?
| | Hypertension | 1 | 2010 | 1242 | 0.050 |
Why?
| | Hospitals | 1 | 2006 | 637 | 0.050 |
Why?
| | Gastric Mucosa | 1 | 2000 | 52 | 0.040 |
Why?
| | Gastrointestinal Motility | 1 | 2000 | 26 | 0.040 |
Why?
| | Methadone | 1 | 2001 | 92 | 0.040 |
Why?
| | Subretinal Fluid | 1 | 2020 | 1 | 0.040 |
Why?
| | Stomach | 1 | 2000 | 109 | 0.040 |
Why?
| | Lasers, Semiconductor | 1 | 2020 | 12 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2020 | 19 | 0.040 |
Why?
| | Therapeutic Index | 1 | 2020 | 2 | 0.040 |
Why?
| | Heart Rate | 1 | 2004 | 802 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 55 | 0.040 |
Why?
| | Coloring Agents | 1 | 2020 | 77 | 0.040 |
Why?
| | Cost Savings | 1 | 2000 | 78 | 0.040 |
Why?
| | Electroretinography | 1 | 2019 | 45 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 516 | 0.040 |
Why?
| | Intestinal Absorption | 1 | 2000 | 99 | 0.040 |
Why?
| | Placebos | 1 | 2000 | 201 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 143 | 0.040 |
Why?
| | Causality | 1 | 2019 | 117 | 0.040 |
Why?
| | Linear Models | 1 | 2001 | 819 | 0.040 |
Why?
| | Child | 2 | 2017 | 20883 | 0.040 |
Why?
| | Nausea | 1 | 1998 | 110 | 0.040 |
Why?
| | Data Collection | 1 | 2001 | 650 | 0.040 |
Why?
| | Vomiting | 1 | 1998 | 128 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 514 | 0.040 |
Why?
| | Parenteral Nutrition, Total | 1 | 1997 | 26 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 149 | 0.040 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2019 | 203 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 141 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2007 | 1902 | 0.030 |
Why?
| | Quality of Life | 2 | 2020 | 2704 | 0.030 |
Why?
| | Netherlands | 1 | 2015 | 77 | 0.030 |
Why?
| | Vision, Ocular | 1 | 2015 | 35 | 0.030 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2015 | 38 | 0.030 |
Why?
| | Crohn Disease | 1 | 1997 | 217 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 255 | 0.030 |
Why?
| | Standard of Care | 1 | 2014 | 72 | 0.030 |
Why?
| | Eye Proteins | 1 | 2014 | 88 | 0.030 |
Why?
| | Acidosis | 1 | 2015 | 89 | 0.030 |
Why?
| | Retinal Detachment | 1 | 2014 | 56 | 0.030 |
Why?
| | Seizures | 1 | 2017 | 402 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 381 | 0.030 |
Why?
| | Axial Length, Eye | 1 | 2013 | 15 | 0.030 |
Why?
| | Rats | 1 | 2001 | 5500 | 0.030 |
Why?
| | ROC Curve | 1 | 2014 | 503 | 0.030 |
Why?
| | Tonometry, Ocular | 1 | 2013 | 88 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1988 | 0.020 |
Why?
| | Risk | 1 | 2014 | 854 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 642 | 0.020 |
Why?
| | Genes, Regulator | 1 | 2010 | 34 | 0.020 |
Why?
| | Antithrombins | 1 | 2010 | 58 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1023 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 330 | 0.020 |
Why?
| | Microcirculation | 1 | 2010 | 145 | 0.020 |
Why?
| | Research Design | 1 | 2015 | 1044 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1839 | 0.020 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 41 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2535 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 280 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 171 | 0.020 |
Why?
| | Drug Costs | 1 | 2008 | 100 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1245 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2073 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 467 | 0.020 |
Why?
| | Thienamycins | 1 | 2005 | 5 | 0.020 |
Why?
| | Colistin | 1 | 2005 | 9 | 0.020 |
Why?
| | Polymyxin B | 1 | 2005 | 20 | 0.020 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 7 | 0.020 |
Why?
| | Platelet Aggregation | 1 | 2005 | 95 | 0.020 |
Why?
| | Platelet Activation | 1 | 2005 | 91 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2070 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 62 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2010 | 749 | 0.010 |
Why?
| | Arginine | 1 | 2005 | 265 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2008 | 526 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1400 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 2009 | 672 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 2003 | 69 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1622 | 0.010 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 499 | 0.010 |
Why?
| | Transcription Factors | 1 | 2010 | 1651 | 0.010 |
Why?
| | Sulfonamides | 1 | 2005 | 496 | 0.010 |
Why?
| | Population Surveillance | 1 | 2004 | 439 | 0.010 |
Why?
| | Liver | 1 | 2010 | 1839 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2013 | 2483 | 0.010 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2001 | 203 | 0.010 |
Why?
|
|
MacLaren's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|